河化股份(000953) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 35,779,363.63, a decrease of 38.43% year-on-year[7] - Net profit attributable to shareholders was CNY -17,917,301.15, an increase of 33.23% in loss compared to the same period last year[7] - Total operating revenue for Q3 2019 was CNY 35,779,363.63, a decrease of 38.3% compared to CNY 58,115,465.97 in the same period last year[39] - Total operating costs for Q3 2019 were CNY 53,967,026.41, down 36.5% from CNY 85,376,143.30 year-on-year[39] - Net loss for Q3 2019 was CNY 17,917,301.15, compared to a net loss of CNY 26,832,653.27 in Q3 2018, representing a 33.5% improvement[41] - Total operating revenue for the current period was CNY 1,170,294.22, a decrease of 79.4% compared to CNY 5,688,542.62 in the previous period[44] - Total operating costs for the current period were CNY 2,194,169.01, down 68.7% from CNY 7,002,383.67 in the previous period[44] - Net profit for the current period was CNY -18,302,810.97, an improvement of 32.5% compared to CNY -27,250,964.00 in the previous period[45] - Total operating revenue for the year-to-date was CNY 123,171,734.39, down 43.2% from CNY 216,431,019.43 in the previous year[47] - Year-to-date net profit was CNY -50,402,237.44, an improvement of 48.3% compared to CNY -97,594,107.55 in the previous year[49] Assets and Liabilities - Total assets decreased by 7.37% to CNY 358,647,671.29 compared to the end of the previous year[7] - The company's total assets decreased to CNY 358.65 million from CNY 387.18 million, reflecting a reduction of about 7.4%[31] - The company's current liabilities increased to CNY 655.04 million from CNY 634.41 million, an increase of approximately 3.5%[32] - The company's total liabilities increased to CNY 657.02 million from CNY 636.99 million, an increase of about 3.1%[32] - The company's total liabilities as of September 30, 2019, were CNY 649,810,635.68, an increase from CNY 624,995,959.43 at the end of 2018, an increase of 4.0%[37] - The company's total equity attributable to shareholders was CNY -302,450,331.40 as of September 30, 2019, compared to CNY -253,685,686.40 at the end of 2018[38] Cash Flow - Cash flow from operating activities increased by 83.49% to CNY -7,324,856.16 year-to-date[7] - The cash flow from operating activities showed a net outflow of CNY 7,324,856.16, an improvement from a net outflow of CNY 44,377,787.74 in the same quarter last year[55] - The total cash inflow from operating activities was CNY 129,420,442.53, down from CNY 243,710,432.82 in the previous year, a decrease of about 46.9%[54] - The total cash outflow from operating activities was CNY 136,745,298.69, compared to CNY 288,088,220.56 in the same period last year, reflecting a decrease of approximately 52.4%[55] - The total cash and cash equivalents at the end of Q3 2019 were CNY 1,776,600.49, down from CNY 4,735,928.44 at the end of Q3 2018, indicating a decrease of about 62.5%[56] Inventory and Receivables - Inventory decreased by 23.93% to CNY 1,440,000, reflecting reduced raw materials and stock[14] - The company reported a significant decrease in inventory, which fell to CNY 14.39 million from CNY 18.92 million, a reduction of about 24.5%[30] - The company's accounts receivable decreased to CNY 4.75 million from CNY 5.36 million, a decline of approximately 11.3%[30] - Inventory as of September 30, 2019, was CNY 13,941,494.19, down 12.1% from CNY 15,862,080.67 at the end of 2018[36] - Other receivables increased significantly to CNY 5,215,574.50 from CNY 1,201,033.23, a rise of 334.4%[36] Expenses - Sales expenses decreased by 49.07% year-on-year, primarily due to reduced sales revenue[15] - Management expenses decreased by 19.88% year-on-year, attributed to production system shutdown[15] - The company reported a significant reduction in management expenses, which were CNY 11,357,621.93 for the current period, down from CNY 20,334,143.47 in the previous period, indicating a focus on cost control[44] - The company's management expenses decreased to CNY 11,494,585.28 from CNY 20,368,045.76, a reduction of 43.5% year-on-year[39] Company Actions and Risks - The company plans to sell assets and issue shares to acquire 93.41% of Nansong Pharmaceutical, raising up to CNY 120 million for transaction costs and fees[16] - The company has been under delisting risk warning since March 13, 2019, due to negative net assets reported in the 2018 audited financial statements[17] - The company has not engaged in any securities investment or entrusted financial management during the reporting period[20][21] - The third quarter report was not audited[60] - The company did not apply new financial instrument standards or new leasing standards for the current year[60] Shareholder Information - Basic and diluted earnings per share for the current period were both CNY -0.0622, compared to CNY -0.0927 in the previous period[45] - Basic and diluted earnings per share for the year-to-date were both CNY -0.1714, compared to CNY -0.3319 in the previous year[49] - The basic and diluted earnings per share for Q3 2019 were both -0.1721, compared to -0.3351 in Q3 2018, showing an improvement of approximately 48.5%[52] Chairman Information - The chairman of the company is Shi Weiguang[61]